Oscillating Positive Expiratory Pressure (OPEP) Devices Market Research Report and Outlook by 2028

The market for oscillating positive expiratory pressure (OPEP) devices is projected to expand from US$ 125.66 million in 2021 to US$ 179.34 million by 2028, reflecting a compound annual growth rate (CAGR) of 5.2% during the period from 2021 to 2028. This report outlines the significant factors propelling market growth and identifies key players along with their recent advancements. The primary drivers for the growth of the OPEP devices market include the increasing incidence of chronic obstructive pulmonary disease (COPD) and asthma, alongside innovations in medical technology. Nevertheless, challenges such as low awareness and restricted access to OPEP devices pose obstacles to market expansion.

OPEP devices have been utilized as an adjunct to traditional chest physiotherapy (CPT) to facilitate the clearance of respiratory secretions in individuals who are unable to cough effectively, particularly those suffering from chronic respiratory conditions. The application of OPEP devices remains limited in chronic airway diseases, including cystic fibrosis, bronchiectasis, bronchitis, bronchial asthma, and primary ciliary dyskinesia syndrome. In the context of COPD, OPEP devices play a crucial role in aiding sputum clearance. These devices are designed to assist in the removal of mucus from the airways, promoting relaxation of the lung walls and thereby enhancing the ease of breathing. The increasing prevalence of COPD and cystic fibrosis is significantly driving the demand for devices that facilitate mucus clearance.

The OPEP devices market is categorized by product type into three segments: mouthpiece PEP devices, face mask PEP devices, and bottle PEP devices. In 2021, the mouthpiece PEP devices segment accounted for the largest market share. Furthermore, it is expected to achieve a CAGR of 5.3% throughout the forecast period. Mouthpiece PEP devices are effective in mucus removal from the lungs and can also help prevent lung collapse or reopen collapsed areas. A key factor contributing to the growth of the mouthpiece PEP devices market is the increasing elderly population, which is accompanied by a rise in chronic conditions such as COPD and asthma. According to the Centers for Disease Control and Prevention (CDC), approximately 9 million individuals were projected to be diagnosed with chronic bronchitis by 2020, thereby amplifying the demand for mouthpiece devices.

In terms of indications, the global OPEP devices market is divided into several categories: chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiectasis, cystic fibrosis, and others. The distribution channels for these devices are segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest market share in 2021. Research published in the Journal of Allergy and Clinical Immunology in 2020 indicates that the rising prevalence of chronic diseases is a significant factor driving the growth of hospital pharmacies.

To compile the report on the OPEP devices market, various primary and secondary sources were consulted. Notable references include the Centers for Disease Control and Prevention (CDC), Health Promotion and Chronic Disease Prevention, the National Health Survey from Social Welfare, the World Heart Federation, the Australian Bureau of Statistics, the National Center for Biotechnology Information (NCBI), and the World Health Organization (WHO).